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Introduction: In addition to the pivotal roles of mast cells in allergic diseases, recent data suggest that mast cells
play crucial roles in a variety of autoimmune responses. However, their roles in the pathogenesis of autoimmune
skeletal muscle diseases have not been clarified despite their distribution in skeletal muscle. Therefore, the objective
of this study is to determine the roles of mast cells in the development of autoimmune skeletal muscle diseases.
Methods: The number of mast cells in the affected muscle was examined in patients with dermatomyositis (DM) or
polymyositis (PM). The susceptibility of mast cell-deficient WBB6F1-KitW/KitWv mice (W/Wv mice) to a murine model
of polymyositis, C protein-induced myositis (CIM), was compared with that of wild-type (WT) mice. The effect of
mast cell reconstitution with bone marrow-derived mast cells (BMMCs) on the susceptibility of W/Wv mice to CIM
was also evaluated.
Results: The number of mast cells in the affected muscle increased in patients with PM as compared with patients
with DM. W/Wv mice exhibited significantly reduced disease incidence and histological scores of CIM as compared
with WT mice. The number of CD8+ T cells and macrophages in the skeletal muscles of CIM decreased in W/Wv mice
compared with WT mice. Engraftment of BMMCs restored the incidence and histological scores of CIM in W/Wv mice.
Vascular permeability in the skeletal muscle was elevated in WT mice but not in W/Wv mice upon CIM induction.
Conclusion: Mast cells are involved in the pathogenesis of inflammatory myopathy.Introduction
Mast cells have long been recognized as the major ef-
fector cells in allergic diseases such as asthma, allergic
rhinitis, and urticaria [1,2]. In addition, recent studies
have revealed new roles of mast cells in the pathogenesis of
autoimmune disease models (reviewed in [3]), including
autoantibody-mediated arthritis [4], experimental allergic
encephalomyelitis [5], and insulin-dependent diabetes
mellitus [6]. Various aspects of mast cell functions in
tissue-specific autoimmune diseases might be due to its
distribution in anatomical sites such as joints, central
nervous system, and pancreas. Although mast cells are
also located in skeletal muscle [7], their roles in the patho-
genesis of skeletal muscle diseases have not been clarified.* Correspondence: suzuki_k@faculty.chiba-u.jp; nakajimh@faculty.chiba-u.jp
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reproduction in any medium, provided the orDermatomyositis (DM) and polymyositis (PM) are auto-
immune myopathies characterized clinically by proximal
muscle weakness, muscle inflammation and destruction,
and responsiveness to immunosuppressive agents [8]. DM
is characterized pathologically by the presence of atrophic,
degenerating, or regenerating myofibers and inflammatory
cells, composed of B cells along with a small number of
CD4+ plasmacytoid dendritic cells, within the perifascicu-
lar areas [9]. On the other hand, PM is characterized by
the presence of inflammatory cells in the endomysium of
skeletal muscle, which are largely composed of CD8+ T
cells and macrophages [9]. Recently, Sugihara et al. have
established a murine model of polymyositis, which is called
C protein-induced myositis (CIM) [10], and have shown
that mice with CIM show pathological features similar to
human polymyositis, including a massive infiltration of
CD8+ T cells and macrophages in the endomysium of skel-
etal muscle [10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathogenesis of autoimmune skeletal muscle diseases,
we quantified mast cell numbers in muscle tissue samples
obtained by muscle biopsies from patients with DM or
PM. We also examined the role of mast cells in the patho-
genesis of CIM. Our findings suggest that mast cells are
involved in the pathogenesis of inflammatory myopathy.
Materials and methods
Patients and samples
Fifteen patients with DM and 12 patients with PM, who
were admitted to Chiba University Hospital or National
Hospital Organization Shimoshizu Hospital between 2004
and 2012 because of newly diagnosed DM/PM according
to the criteria developed by Bohan and Peter [11,12], were
enrolled in this study. The study design was approved by
the ethics committees of Chiba University Hospital and
Shimoshizu Hospital. Muscle specimens were obtained by
muscle biopsy from biceps brachii or quadriceps femoris
of the patients before treatment. All patients provided
written informed consent. As controls, muscle samples
from patients with muscular dystrophy—Becker muscular
dystrophy (n = 3) and Limb-Girdle muscular dystrophy
(n = 3)—were also analyzed.
Mast cell staining
Sections of muscle samples were fixed and stained with
toluidine blue in accordance with a standard protocol.
In some experiments, sections of muscle samples were
stained with anti-human mast cell tryptase antibody
(AA1; Dako Denmark A/S, Glostrup, Denmark) in accord-
ance with the instructions of the manufacturer.Histological analysis
Sections of muscle samples were fixed and stained with
hematoxylin-eosin (H&E) in accordance with the stand-
ard protocol. The intensity of inflammatory infiltrate
was evaluated by semi-quantitative scoring system (5-
point grading) as described previously [13].Mice
Genetically mast cell-deficient WBB6F1-KitW/KitWv mice
(W/Wv mice), congenic WBB6F1-Kit+/Kit+ mice, and
C57BL/6 J mice were purchased from SLC (Shizuoka,
Japan). Enhanced green fluorescent protein transgenic
(eGFP-Tg) mice were previously described [14]. All mice
were housed in microisolator cages under specific pathogen-
free conditions, and all experiments were performed in
accordance with the guidelines of Chiba University. Ex-
perimental procedures were approved by biomedical re-
search ethics committee of the Graduate School of
Medicine at Chiba University (approval ID A22-149).Induction of C protein-induced myositis
Recombinant murine skeletal C protein fragment 2 was
prepared as described previously [15]. For the induction of
CIM, 8- to 10-week-old female mice were immunized
intradermally at the back and foodpads with 200 μg of the
C protein fragment 2 emulsified in complete Freund’s ad-
juvant (CFA) containing 100 μg of heat-killed Mycobacter-
ium butyricum (Difco, Detroit, MI, USA). Pertussis toxin
(0.5 μg/mouse; Seikagaku Kogyo, Tokyo, Japan) was
injected to the mice intraperitoneally at the same time. As
a control, mice were injected intradermally with CFA in
the absence of C protein fragment 2 and injected intraper-
itoneally with pertussis toxin. At indicated days after the
induction of CIM, histological analysis was performed on
proximal muscles (hamstrings and quadriceps). Histo-
logical scores were evaluated by a pathologist in a blinded
manner as described previously [10]. Necrotic muscle fi-
bers were defined by decreased H&E staining intensity,
which was occasionally accompanied by mononuclear cell
infiltration in regenerative processes, and total necrotic
area was evaluated as described previously [16]. In pre-
liminary experiments, we confirmed necrotic muscle fi-
bers by investigating serial sections of muscle samples
with H&E staining and nicotinamide adenine dinucleo-
tide hydrogen-tetrazolium reductase (NADH-TR) stain-
ing (data not shown).Quantification of degranulating mast cells in skeletal muscle
At indicated days after the induction of CIM, mast cells in
the skeletal muscle were assessed for intact phenotype ver-
sus degranulating phenotype in a blinded manner by using
morphologic criteria as described previously [4]. In brief,
mast cells were identified as cells containing granules
stained with toluidine blue. Degranulating cells were de-
fined by the presence of granules outside the cell border
with coincident vacant granule space within the cell border.
Only cells in which a nucleus was present were counted.Detection of CD8+ T cells and macrophages at the sites of
C protein-induced myositis
Twenty-one days after the induction of CIM, a block of
proximal muscles (hamstring and quadriceps) was fixed
overnight in 4% paraformaldehyde in phosphate-buffered
saline (PBS), equilibrated in 30% sucrose in PBS, embedded
in OCT compound, and kept at −80°C. Cryosections were
stained with anti-CD8 antibody (53-6-7; BD PharMingen,
San Diego, CA, USA) or anti-F4/80 antibody (BM8;
eBioscience, San Diego, CA, USA). After washing, sections
were stained with TO-PRO-3 iodide (Invitrogen, San Diego,
CA, USA) for nuclear staining and analyzed by using LSM
710 confocal laser microscopy (Carl Zeiss Microimaging,
Oberkochen, Germany).
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marrow-derived mast cells
Primary culture of interleukin-3-dependent bone marrow-
derived mast cells (BMMCs) was prepared from 6- to 8-
week-old eGFP-Tg mice and maintained as previously
described [17]. Cultured BMMCs from eGFP-Tg mice
were harvested and injected intravenously into W/Wv
mice (1 × 107 cells per mouse). Four weeks after the trans-
plantation, CIM was induced in these mice.
Detection of engrafted mast cells from eGFP-Tg mice in
skeletal muscle
Four weeks after the transfer of BMMCs prepared from
eGFP-Tg mice, a block of proximal muscles was fixed,
equilibrated, and embedded in OCT compound as de-
scribed above. Cryosections were stained with TO-PRO-3
iodide, and the presence of eGFP+ cells was analyzed by
using LSM 710.
Evaluation of vascular permeability
Vascular permeability was evaluated as described else-
where [18]. In brief, at indicated days after CIM induc-
tion, Evans blue dye (1% in saline, 100 μL/mouse) was
intravenously injected into mice under anesthesia with
pentobarbital (100 mg/kg). Forty minutes later, mice
were perfused intracardially with PBS until no more ef-
flux of blue dye was seen in the right atrium. A block of
proximal muscles was fixed and embedded in OCT com-
pound as described above. The leakage of Evans blue
dye in the tissue was assessed by the presence of red
fluorescence of Evans blue dye in extravascular spaces
by using LSM 710 and was quantified with National In-
stitutes of Health ImageJ software.
Evaluation of anti-C protein antibodies
The levels of anti-C protein antibodies in sera were evalu-
ated by enzyme-linked immunosorbent assay. In brief, re-
combinant C protein (10 μg/mL in 0.05% Tween 20 in
PBS) was adsorbed onto flat-bottomed microtiter plates
overnight at 4°C. After blocking with 1% bovine serum al-
bumin in PBS, plates were incubated with sera diluted at
the indicated ratio in 0.05% Tween 20 in PBS. Anti-C pro-
tein antibodies bound to the plate coated with C protein
were detected by using alkaline phosphatase-conjugated,
affinity-purified antibody against IgE, IgG, IgG1, IgG2a,
IgG2b, IgG2c, and IgG3 (SouthernBiotech, Birmingham,
AL, USA). Assays were developed with phosphatase sub-
strate (Sigma-Aldrich, St. Louis, MO, USA), stopped with
0.6 M NaOH, and read at a wavelength of 405 nm on a
microplate reader.
Data analysis
Data are summarized as mean ± standard deviation (SD)
or median (interquartile range). The statistical analysisof the results was performed by an unpaired t test, a
Wilcoxon test, Fisher’s exact test, or a Spearman rank
correlation coefficient as appropriate. P values of less
than 0.05 were considered significant.
Results
The numbers of mast cells are increased in muscle
samples of patients with polymyositis
To assess the roles of mast cells in autoimmune skeletal
muscle diseases, we first examined the numbers of mast
cells in muscle biopsy samples from patients with new-
onset DM and PM. Demographics and disease characteris-
tics of patients with DM (n = 15) and PM (n = 12) are
shown in Table 1. There was no significant difference be-
tween DM and PM patients in age, sex, disease duration,
the frequency of anti-nuclear Ab-positive or anti-Jo-1 Ab-
positive, serum levels of creatine kinase (CK), manual
muscle testing score, and the frequency of interstitial lung
disease or allergic diseases (Table 1). The number of mast
cells that were identified as toluidine blue-positive cells
(Figure 1a) in muscle biopsy samples was significantly
higher in patients with PM than in patients with DM (PM
5.44 versus DM 0.88, median of the number of mast cells/
mm2, P <0.0001) or in patients with muscular dystrophy:
Becker muscular dystrophy (n = 3), Limb-Girdle muscular
dystrophy (n = 3) (Figure 1b). The presence of mast cells
in muscle biopsy samples in patients with PM was con-
firmed by immunohistological analysis with antibody
against mast cell tryptase (Figure 1c), another confirma-
tory marker for mast cells [19]. In addition, there is a
modest correlation between the number of mast cells in
muscle samples and the levels of CK in patients with PM
(r = 0.557, P = 0.060) (Figure 1d) but not in patients with
DM (P = 0.454, P = 0.092), consistent with a previous re-
port showing that there is no obvious difference in the
number of mast cells in muscle tissue between patients
with juvenile DM and control subjects [20]. The number
of mast cells in muscle samples was also correlated with
the intensity of inflammatory infiltrate in patients with
PM (P = 0.745, P = 0.007; Figure 1e) but not in patients
with DM (P = −0.369, P = 0.467).
The susceptibility to C protein-induced myositis is
attenuated in mast cell-deficient W/Wv mice
To further assess the role of mast cells in the pathogen-
esis of PM, we first examined the numbers of mast cells
in skeletal muscle with or without the induction of a
murine model of PM, CIM. Consistent with a previous
report [7], mast cells were present in the endomysium,
perivascular area, and perimysium of skeletal muscle in
C57BL/6 J mice without CIM induction (Figure 2a and
Table 2). Importantly, the number of mast cells in skel-
etal muscle was increased by CIM induction (Table 2),
and mast cells were frequently located in the center of
Table 1 Characteristics of the patients with dermatomyositis/polymyositis
DM PM P value
n = 15 n = 12
Age, years 67.0 (45.5-70.0) 54.0 (36.0-63.0) 0.556
Sex, % female 12 (80) 12 (100) 0.108
Disease duration, months 3.00 (2.00-4.00) 3.25 (2.75-6.00) 0.798
Anti-nuclear Ab-positive, % 8 (53.3) 6 (50.0) 0.564
Anti-Jo-1-Ab-positive, % 2 (13.3) 1 (8.3) 0.817
CK, IU/l 2,913 (499-9,029) 1,929 (1,219-3,552) 1.000
MMT score, 0-90 76.0 (72.0-78.5) 75.0 (70.0-80.0) 0.814
Number of patients with ILD, % 6 (40.0) 4 (33.3) 0.734
Allergic disease, % 1 (6.67) 1 (8.33) 0.695
Values shown are median (interquartile range). P values were calculated by the Wilcoxon test or Fisher’s exact test. Ab, antibody; CK, creatine kinase; DM,
dermatomyositis; ILD, interstitial lung disease; MMT, manual muscle testing; PM, polymyositis.
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CIM induction (Figure 2a). Frequency of degranulating
mast cells was increased in C57BL/6 J mice at 10 and
21 days after CIM induction (Figure 2b) but not in control
mice that were injected with CFA in the absence of C pro-
tein (data not shown).
To evaluate the role of mast cells in the development of
CIM, we next compared the incidence and severity of CIM
between mast cell-deficient WBB6F1-KitW/KitWv mice (W/
Wv mice) and their congenic wild-type WBB6F1-Kit+/Kit+
mice (WT mice). Histological analysis of skeletal muscle at
21 days after CIM induction revealed that W/Wv mice ex-
hibited significantly reduced inflammatory cell infiltration
as compared with WT mice (WT 2.1 ± 0.8 versus W/Wv
0.7 ± 0.5, mean ± SD of histological score, P <0.01) (Figure 3)
and reduced incidence (WT 100% versus W/Wv 70%).
Necrotic muscle area was also reduced in W/Wv mice as
compared with WT mice (P <0.05) (Figure 3). These re-
sults suggest the involvement of mast cells in the patho-
genesis of CIM.
Infiltration of CD8+ T cells and macrophages in skeletal
muscle is reduced in C protein-induced myositis in
W/Wv mice
We next examined the number of leukocytes infiltrating
into skeletal muscle (hamstrings) at 21 days after CIM in-
duction by immunohistochemistry. As shown in Figure 4a
and 4c, the number of CD8+ T cells was reduced in W/Wv
mice as compared with WT mice (WT 253.1 ± 36.5 versus
W/Wv 75.8 ± 27.9 per mm2, mean ± SD, n = 6, P <0.01).
The number of macrophages (F4/80+ cells) was also re-
duced in W/Wv mice as compared with WT mice (WT
1,145.2 ± 62.9 versus W/Wv 324.2 ± 41.6 per mm2, mean ±
SD, n = 6, P <0.01) (Figure 4b and 4d). These results indi-
cate that mast cells play a crucial role in the accumulation
of CD8+ T cells and macrophages at the sites of CIM.C protein-specific IgGs are similarly produced in wild-type
mice and W/Wv mice upon C protein-induced
myositis induction
Because mast cells play a crucial role in the induction
of CIM (Figures 3 and 4), we next examined the levels
of C protein-specific IgE and IgGs in sera. As shown in
Figure 5a and 5b, C protein-specific IgG was detectable
but C protein-specific IgE was undetectable in sera of
WT mice at 21 days after CIM induction. In addition, C
protein-specific IgG subclasses were similarly produced
in WT mice and W/Wv mice at 21 days after CIM in-
duction (Figure 5c). C protein-specific IgE was un-
detectable in W/Wv mice (data not shown).
The susceptibility to C protein-induced myositis is
restored in mast cell-engrafted W/Wv mice
To further examine whether mast cells are involved in
the pathogenesis of CIM, we next analyzed the inci-
dence and severity of CIM in W/Wv mice with or with-
out the reconstitution of mast cells. In this experiment,
to easily confirm the reconstitution of mast cells,
BMMCs from eGFP-Tg mice were injected intraven-
ously into W/Wv mice. eGFP+ cells were detected in
skeletal muscle in BMMC-engrafted W/Wv mice but
not in control W/Wv mice at 4 weeks after transplant-
ation (Figure 6a), although the number of mast cells
in the endomysium of BMMC-engrafted W/Wv mice
was less than that of WT control mice (BMMC-
engrafted W/Wv 3.6 ± 0.9 versus WT 6.3 ± 1.0, mean ±
SD, P <0.01). We then induced CIM in BMMC-
engrafted W/Wv mice at 4 weeks after transplantation.
As compared with control W/Wv mice, BMMC-
engrafted W/Wv mice exhibited strong inflammatory
cell infiltration in skeletal muscle (W/Wv 0.6 ± 0.5 versus
BMMC-engrafted W/Wv 1.6 ± 0.5, mean ± SD of histo-
logical score, P <0.01) (Figure 6b) and increased incidence
Figure 1 Increased numbers of mast cells in the affected muscle in patients with polymyositis (PM). (a) Muscle sections from
patients with PM were stained with toluidine blue. Arrowheads indicate mast cells. (b) Muscle sections from patients with PM (n = 12),
dermatomyositis (DM) (n = 15), and muscular dystrophy (n = 6) were stained with toluidine blue, and the numbers of mast cells were
counted in the specimens. Shown is the number of mast cells/mm2 with median (horizontal bar) in patients with PM, DM, and muscular
dystrophy (PM versus DM, P <0.0001; PM versus muscular dystrophy, P = 0.002). (c) Muscle sections from patients with PM were stained with
anti-human mast cell tryptase antibody. Correlation of the number of mast cells in muscle tissue with serum creatine kinase (CK) level
(n = 12) (d) or histological score (n = 12) (e). Each point represents an individual patient with PM.
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rotic muscle area was also increased in BMMC-engrafted
W/Wv mice as compared with that in control W/Wv mice
(P <0.05) (Figure 6b). These data indicate that mast cells
play a crucial role in the pathogenesis of CIM.Vascular leakage in skeletal muscle is detected in wild-type
mice but not in W/Wv mice upon C protein-induced
myositis induction
A recent report has shown that mast cell-mediated increase
of vascular permeability is involved in the recruitment of
Figure 2 Histological analysis of skeletal muscle in mice with C protein-induced myositis (CIM). (a) Mice were immunized with murine
skeletal C protein fragment or vehicle as described in Materials and methods. Twenty-one days after the immunization, specimens of proximal
muscle were stained with toluidine blue. Arrowheads indicate mast cells. (b) Kinetic analysis of mast cell degranulation. Mice were immunized
with murine skeletal C protein fragment, and at indicated days after the immunization, the frequency of degranulating mast cells in skeletal
muscle was evaluated as described in Materials and methods. Dots show the percentage of degranulating mast cells of individual mice, and
horizontal bars show mean percentages of degranulating mast cells. n = 6 mice at each time point, *P <0.01.
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ine model of arthritis [21]. We therefore assessed vascular
permeability in skeletal muscle at 10 and 21 days after CIM
induction by using Evans blue leakage assay. Importantly,leakage of Evans blue dye in skeletal muscle was detected
in WT mice but not in W/Wv mice at 10 and 21 days after
CIM induction (Figure 7). These results indicate that mast
cells are required for an increase in vascular permeability in
Table 2 Kinetic analysis of the numbers of mast cells in
skeletal muscle in wild-type mice upon C protein-induced
myositis induction
Days after immunization
Site Day 0 Day 10 Day 21
Endomysium 6.3 ± 1.0 10.5 ± 3.7 13.5 ± 7.4a
Perivascular 2.2 ± 1.0 3.3 ± 1.0 5.0 ± 3.6a
Perimysium 1.3 ± 1.3 3.3 ± 1.0 2.8 ± 0.5a
Mast cells were identified as toluidine blue-positive cells. The number of mast
cells in each mouse was expressed as the maximum number of cells/100×
magnification field in quadriceps. aP <0.05 as compared with mast cell
numbers at each site at day 0.
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vascular permeability may be involved in mast cell-
mediated enhancement of pathological changes in CIM.
Discussion
In this study, we show that mast cells are involved in the
pathogenesis of inflammatory myopathy. We found thatFigure 3 Attenuation of C protein-induced myositis (CIM) in mast cell
mice (n = 10) and control congenic wild-type (WT) mice (n = 10). Twenty-o
hematoxylin and eosin. Representative photomicrographs, histological scor
necrotic muscle area (right panel) are shown. Dots show histological score
show the mean. *P <0.01.the number of mast cells in the affected muscle was in-
creased in patients with PM as compared with that in
patients with DM (Figure 1b). We also found that the
number of degranulating mast cells was increased in the
endomysium of skeletal muscle upon CIM induction
(Figure 2b). Moreover, we found that the susceptibility
to CIM was reduced in mast cell-deficient W/Wv mice
as compared with WT mice (Figures 3 and 4) and that
the reduced susceptibility of W/Wv mice to CIM was re-
stored by the reconstitution of mast cells (Figure 6).
Taken together, these results suggest that mast cells play
roles in the pathogenesis of PM.
We show that the number of mast cells is increased in
the affected muscles in patients with PM. Although DM
and PM share many clinical characteristics such as
proximal muscle weakness, muscle inflammation, and
extramuscular manifestations (including interstitial lung
disease), the histopathologic features of the affected
muscle are different between DM and PM [9]. DM is
characterized by the presence of atrophic, degenerating,-deficient W/Wv mice. CIM was induced in mast cell-deficient W/Wv
ne days after the induction, specimens of muscle were stained with
es of inflammatory mononuclear cell infiltration (left panel), and
and necrotic muscle area of individual mouse, and horizontal bars
Figure 4 (See legend on next page.)
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Figure 4 Decreased numbers of CD8+ T cells and macrophages at the sites of C protein-induced myositis (CIM) in mast cell-deficient
W/Wv mice. CIM was induced in W/Wv mice and control congenic wild-type (WT) mice. Twenty-one days after the induction, specimens of
muscle were stained with anti-CD8 antibody, anti-F4/80 antibody, and TO-PRO-3 (nuclear staining). Representative photomicrographs of CD8+
cells (a) and F4/80+ cells (b) in skeletal muscle in W/Wv mice and WT mice are shown. Mean ± standard deviation of the numbers of CD8+ cells
(c) and F4/80+ cells (d) (per mm2) is shown. n = 6 mice in each group. *Significantly different from the mean value of WT mice (P <0.01). ND,
not detectable.
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[9], whereas PM is characterized by the presence of inflam-
matory cells in the endomysium of skeletal muscle, which
are largely composed of CD8+ T cells and macrophages [9].
In addition, we showed that the number of mast cells in the
affected muscle was increased in PM as compared with that
in DM (Figure 1b). On the other hand, a recent study has
suggested that plasmacytoid dendritic cells play an import-
ant role in the pathogenesis of DM [22]. Taken together,
these data suggest that critical effector cells are different in
the pathogenesis of DM and PM.
We show a crucial role of mast cells in causing CIM.
Although it has long been known that mast cells exist inFigure 5 Levels of C-protein-specific immunoglobulins in sera. Sera w
21 days after C protein-induced myositis (CIM) induction, diluted to indicat
for anti-C protein IgG (a) or anti-C protein IgE (b). The optical density (OD)
those in control mice. (c) Sera obtained from WT mice and W/Wv mice at 21
ELISA for IgG subclasses against C protein. Data are mean ± standard deviatioskeletal muscle [7], pathophysiological significance of mast
cells in skeletal muscle has not been clarified. Mast cells
are critical effector cells in allergic diseases and other IgE-
associated acquired immune responses, including protec-
tion against parasites [1,23]. In addition, recent studies
have revealed that mast cells are involved in the pathogen-
esis of autoimmune disease models [3,4]. On the other
hand, in some circumstances, mast cells exhibit anti-
inflammatory and immunosuppressive functions [24,25],
suggesting that mast cells have both positive and negative
impacts on immune responses. We found that mast cell-
deficient W/Wv mice exhibited reduced susceptibility to
CIM as compared with WT mice (Figures 3 and 4) andere obtained from wild-type (WT) mice before (as a control) and at
ed rates, and subjected to enzyme-linked immunosorbent assay (ELISA)
levels of anti-C protein IgE in CIM-induced mice were nearly identical to
days after CIM induction were diluted by a 100-fold and subjected to
n; n = 5, each.
Figure 6 Restoration of C protein-induced myositis (CIM) in W/Wv mice engrafted with mast cells. (a) Cultured bone marrow-derived
mast cells (BMMCs) of enhanced green fluorescent protein (eGFP) transgenic mice (1 × 107 cells) were injected intravenously into 6-week-old
W/Wv mice (BMMC-engrafted W/Wv [W/Wv + BMMCs] mice). Four weeks after the transplantation, the presence of mast cells in skeletal muscle
was evaluated. Representative photomicrographs of eGFP+ mast cells in skeletal muscle in W/Wv mice (as a control) and BMMC-engrafted
W/Wv mice are shown. (b) Four weeks after the transplantation of BMMCs, CIM was induced in BMMC-engrafted W/Wv mice. CIM was induced
in WT mice and W/Wv mice as controls. Twenty-one days after the induction, specimens of muscle from WT mice (n = 10), W/Wv mice (n = 11),
and BMMC-engrafted W/Wv mice (n = 11) were stained with hematoxylin and eosin. Representative photomicrographs, histological scores
(left panel), and necrotic muscle area (right panel) are shown. *P <0.01, **P <0.05.
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by the reconstitution of mast cells (Figure 6). Although we
could not exclude the possibility that other abnormalities
of W/Wv mice such as anemia and reduced numbers of
neutrophils and basophils [1,26] are also involved in the
reduced susceptibility to CIM, our results strongly suggest
that mast cells in skeletal muscle play an important role in
the development of CIM.Regarding the mechanism underlying mast cell-mediated
exacerbation of autoimmune diseases, Binstadt et al. have
shown an attractive mechanism for achieving organ-
specific autoimmune diseases, in which mast cells increase
disease severity by enhancing vascular permeability at the
site of inflammation [21]. The authors have demonstrated
that arthritogenic antibodies activate mast cells and that
histamine and serotonin released from activated mast cells
Figure 7 Vascular leakage in skeletal muscle in wild-type (WT) mice and W/Wv mice upon C protein-induced myositis (CIM) induction.
CIM was induced in WT mice and W/Wv mice, and at 10 and 21 days after the induction, Evans blue leakage in skeletal muscle was evaluated as
described in Materials and methods. (a) Representative photomicrographs of phase contrast, Evans blue leakage, and merged image are shown.
Arrowheads indicate red fluorescence by Evans blue dye leakage in extravascular space in the perimysium. (b) Mean ± standard deviation of the
mean fluorescence intensity (MFI) of Evans blue dye in the perimysium is shown. n = 6 mice in each group. *Significantly different from the mean
value of WT mice (P <0.01).
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tined to develop arthritis [21]. Here, we found an in-
crease of vascular permeability in the endomysium of
skeletal muscle in WT mice but not in W/Wv mice
upon CIM induction (Figure 7). Notably, an increase of
vascular permeability was detected in WT mice at
10 days after the induction, when degranulating mast cells
in skeletal muscle were increased (Figure 2b). These data
suggest that mast cells promote the recruitment of inflam-
matory cells into the endomysium of skeletal muscle in
CIM in part by increasing vascular permeability.
Accumulating evidence has shown that muscle injury in
patients with PM is driven by cytotoxic CD8+ T cells [27].
In CIM, recent studies have also shown that CD8+ T cellsare accumulated at the site of inflammation and play a
critical role in muscle injury in a perforin-dependent man-
ner [10,16]. In this study, we found that the numbers of
CD8+ T cells were reduced in the affected muscle in CIM
in mast cell-deficient W/Wv mice (Figure 4). We also
found that inflammatory cell infiltration and necrotic
muscle area were significantly reduced in W/Wv mice as
compared with those in WT mice (Figure 3). These find-
ings suggest that the impaired infiltration of CD8+ T cells
into the inflammatory sites is involved in the reduced sus-
ceptibility of W/Wv mice to CIM.
We also show that the numbers of macrophages in
the affected muscle in CIM are reduced in W/Wv mice
(Figure 4). Regarding the mechanism underlying the
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http://arthritis-research.com/content/16/2/R72reduced accumulation of macrophages at the site of CIM
in W/Wv mice, we found that the expression of monocyte
chemoattractant protein-1 (MCP-1) in skeletal muscle was
reduced in W/Wv mice as compared with that in WT
mice (data not shown). It has been shown that mast cells
produce MCP-1 and induce the accumulation of macro-
phages in a murine model of asthma [28]. In preliminary
experiments, we also found that MCP-1-expressing mast
cells were detected at the site of CIM in W/Wv mice
engrafted with eGFP+ BMMCs (data not shown). There-
fore, it is suggested that mast cells directly induce the ac-
cumulation of macrophages at the sites of CIM through
the production of MCP-1.
At present, the signal that activates mast cells at the site
of CIM remains unknown. The importance of Fc receptor
family members expressed on mast cells has been revealed
in other models of autoimmune diseases such as experi-
mental allergic encephalomyelitis [27] and K/BxN arthritis
[28]. In this regard, however, it has been shown that CIM
is normally induced in mice lacking B cells [10], indicating
that immunoglobulins are not required for the develop-
ment of CIM. The possibility that mast cells are activated
by some endogenous danger signals that possess proin-
flammatory potential need to be addressed in the future.
Conclusions
Our results indicate that mast cells play a role in the
pathogenesis of inflammatory myopathy. Although fur-
ther studies are required, our results should add a new
insight into the pathophysiological roles of mast cells in
autoimmune diseases and suggest that mast cells could
be possible therapeutic targets in patients with PM.
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